Globus Medical stock analysis
Want to see GMED full AI Analyst Report?
Globus Medical (GMED) Stock Price & Analysis
GMED Stock Chart & Stats
- Day’s Range
- $66.63 - $69.54
- 52-Week Range
- $66.63 - $101.40
- Previous Close
- $68.60
- Volume
- N/A
- Average Volume (3M)
- 1.80M
- Market Cap
- $9.09B
- Enterprise Value
- $9.78B
- Total Cash (Recent Filing)
- $517.43M
- Total Debt (Recent Filing)
- $107.55M
- Price to Earnings (P/E)
- 16.2
- Beta
- 0.74
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 1.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage gives Globus Medical substantial financial resilience and flexibility. The company can fund product development, technology investments and potential strategic actions without relying heavily on debt, while stronger equity supports stability through operating volatility.
Strong Cash Generation
Robust operating and free cash flow indicate strong earnings quality and meaningful internal funding capacity. This supports continued innovation, commercial investment and shareholder returns while reducing dependence on external financing during periods of slower revenue growth.
Technology And Product Expansion
Rapid adoption of enabling technologies can deepen Globus’s role in surgical workflows and support recurring procedure-related demand. Greater installed-base utilization also creates a platform for future implant growth, technology attachments and differentiated clinical offerings.
Bears Say
Revenue Growth Deceleration
The reduced outlook signals that near-term growth is below prior expectations, limiting confidence in the pace of expansion over the next several quarters. Delayed Spine launches and weaker Nevro performance also make the consolidated revenue trajectory less predictable.
Nevro Revenue Weakness
Persistent Nevro revenue and trial-volume weakness is a material drag on consolidated performance. Recovery depends on rebuilding sales productivity and procedure adoption, creating execution risk even though management reported improving Nevro profitability.
Competitive Pricing Pressure
Ongoing biologics pricing competition can constrain revenue realization and make margin improvement harder to sustain in that product area. The company’s effort to increase attachment rates may help volume, but it does not remove the structural pressure on pricing.
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
What is Globus Medical’s market cap?
When is Globus Medical’s upcoming earnings report date?
How were Globus Medical’s earnings last quarter?
Is Globus Medical overvalued?
Does Globus Medical pay dividends?
What is Globus Medical’s EPS estimate?
How many shares outstanding does Globus Medical have?
What happened to Globus Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Globus Medical?
What is the TipRanks Smart Score and how is it calculated?
Globus Medical Stock Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Keith W. Pfeil
- Employees
- 6,000
- Website
- www.globusmedical.com
- Address
- 2560 General Armistead Avenue, Audubon, PA, 19403-5214, US
Globus Medical (GMED) Earnings & Revenues
GMED Earnings Call
Earnings Call SentimentPositive
The call was broadly constructive, supported by record free cash flow, expanding margins, strong Trauma and Enabling Technologies growth, continued product launches and maintained EPS guidance. However, near-term performance is being constrained by the 25.7% Nevro revenue decline, delayed Spine launches, weaker competitive recruiting, international softness and a reduction in 2026 revenue guidance. Management remained confident in the longer-term trajectory, particularly for 2027.
View all GMED earnings summariesGMED Net sales Breakdown
- 92.34% Musculoskeletal Solutions
- 7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |











